CLINUVEL Bulletin Edition 01
The first in a new series providing updates on CLINUVEL's Brand Architecture,...
Read More
CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...
Read More
Expansion of CLINUVEL’s global porphyria programs
CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...
Read More
News Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
News Communiqué I - Ms Cristina Ramos
Introducing CLINUVEL’s next Intriguing Personality (CUVIP), Ms Cristina Ramos.
Read More
News Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read More
Investor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read More
First stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read More
Technical note: Arterial Ischaemic Stroke (AIS)
This Technical Note provides further detail on the current standards of care...
Read More
DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read More
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
News Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More